hepatocellular carcinoma (HCC)
Conditions
Interventions
Experimental group:PARP inhibitor treatment
Sponsors
The Fifth Medical Center of PLA General Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. Patients voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with the follow-up; 2. Patients aged 18 to 75 years, no gender limit; 3. Patients with hepatocellular carcinoma confirmed by histopathology or radiology; 4. Life expectancy of at least 3 months; 5. Patients with Barcelona stage B or C; 6. Patients who have received anthracycline chemotherapy drugs or platinum chemotherapy drugs and whose tumors are resistant; 7. Platelet count>=60x10^9/L, prothrombin time prolonged <=6 seconds; 8. The patient agrees to undergo high-throughput sequencing testing.
Exclusion criteria
Exclusion criteria: 1. Coagulation disorder with obvious bleeding tendency; 2. The patient needs to receive long-term anticoagulation or antiplatelet therapy, and the drug cannot be stopped; 3. Patients with unstable or active ulcers or gastrointestinal bleeding; 4. Heart disease requiring treatment or poorly controlled blood pressure; 5. Patients with interstitial pneumonia; 6. Hepatic encephalopathy or refractory ascites requiring treatment; 7. There is obvious active infection; 8. Serious insufficiency of vital organs, such as severe cardiopulmonary insufficiency; 9. Other concomitant antitumor therapy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;Overall survival;Disease control rate;Duration of tumor remission;Objective response rate;Security; | — |
Countries
China
Contacts
Public ContactXie Hui
The Fifth Medical Center of PLA General Hospital
Outcome results
None listed